Showing 4451-4460 of 9330 results for "".
- Galderma Mans Up with New Cetaphil Line for Menhttps://practicaldermatology.com/news/cetaphils-newest-line-targets-men/2458690/Galderma Laboratories, L.P is manning up with the launch of a new skin care line for men. The Cetaphil® Men line comprises Cetaphil® Men Daily Face Wash, Cetaphil® Men Daily Face Cloths , Cetaphil® Men Daily Face Lotion SPF 15 , Cetaphil® Men 3-in-1 Active Antibacterial Bar , Cetaphil® Men Dai…
- Tempted by Temptu to Debut at AAD Annual Meetinghttps://practicaldermatology.com/news/tempted-by-temptu-to-debut-at-aad-annual-meeting/2458691/At the upcoming 2016 AAD annual meeting, TEMPTU introduces its groundbreaking TEMPTU Air, the first handheld airbrush makeup device for skin perfection. Using the company’s patented Airpod and Atomized AirFlow™ Technology, TEMPTU Air delivers a micro-fine mist that floats onto the skin, creating w…
- Good Deal: DS Healthcare Acquires Radiancy, Neovahttps://practicaldermatology.com/news/good-deal-ds-healthcare-acquires-radiancy-neova/2458692/DS Healthcare Group, Inc. will acquire Radiancy, Inc., and Neova® from PhotoMedex, Inc. The board of directors of both companies have voted unanimously in favor of the transaction, which is structured in two reverse triangular mergers, with a non-dilutive provision. The transaction is expected to …
- New AAD Acne Guidelines Call for Combination Therapyhttps://practicaldermatology.com/news/new-aad-acne-guidelines-call-for-combination-therapy/2458695/Combination therapy is the way forward for treating moderate-to-mild acne, according to new guidelines from The American Academy of Dermatology. For example, antibiotics should be used with topical acne therapy, and patients should continue using topical treatments to manage their condition. Once …
- Caladrius Biosciences Licenses Dermatology Cell Technology to AiVita Biomedicalhttps://practicaldermatology.com/news/caladrius-biosciences-licenses-dermatology-cell-technology-to-aivita-biomedical/2458698/Caladrius Biosciences, Inc., has licensed exclusive global rights to its cell-derived dermatological technology for topical skin applications to AiVita Biomedical, Inc. The company says this transaction supports its strategy to monetize non-core assets. AiVita, a biotechnology company, was founded…
- Novel Jasmonate Compound Takes On Fine Wrinkles, Poreshttps://practicaldermatology.com/news/novel-jasmonate-compound-takes-on-fine-wrinkles-pores/2458704/The active ingredient in Lancome’s Visionnaire family of products safely and effectively helps improve the appearance of fine wrinkles, skin tone and pores, according to a new study in the Feb. 2016 issue of the Journal of Drugs and Dermatology. The ingredient, LR2412-Cx, is among the most widely …
- Traffic-related Air pollution Linked to Facial Lentigeneshttps://practicaldermatology.com/news/traffic-related-air-pollution-linked-to-facial-lentigenes/2458707/High levels of traffic-related air pollution and air pollution-associated gases may increase risk of developing facial lentigenes, new research suggests. "While NO2 exposure is known to be associated with low lung function and lung cancer, the effect of NO2 on human skin has never been investigate…
- Hilary Baldwin, MD, Named Medical Director of ATRChttps://practicaldermatology.com/news/hilary-baldwin-md-named-medical-director-of-atrc/2458710/The newly opened Acne Treatment and Research Center (ATRC) in Morristown, NJ, has tapped Hilary Baldwin, MD, to serve as its medical director. Dr. Baldwin received her BA and MA in biology from Boston University. She became a research assistant at Harvard University before attending Boston Univers…
- Pfizer Outlines Post-Allergan Deal Leadership Team Changeshttps://practicaldermatology.com/news/pfizer-outlines-post-allergan-deal-leadership-team-changes/2458709/Brent Saunders will become President and Chief Operating Officer of the combined Pfizer and Allergan company following the close of the merger deal. In this role, he will over see Pfizer and Allergan’s combined commercial businesses, manufacturing and strategy functions. The combined company will …
- Otsuka Licenses Pre-Phase 3 Topical Atopic Dermatitis Treatment to Medimetrikshttps://practicaldermatology.com/news/otsuka-licenses-pre-phase-3-topical-atopic-dermatitis-treatment-to-medimetriks/2458712/Otsuka Pharmaceutical Co., Ltd. and Medimetriks Pharmaceuticals, Inc. have entered into a licensing agreement granting Medimetriks exclusive development, manufacturing and commercialization rights for OPA-15406 in the U.S. and Puerto Rico. OPA-15406 is a topical, non-steroidal phosphodiesterase IV…